UK Experimental AMR Payment Program “On Track”
Two Antibiotics To Be Identified For Assessment By Year-End
Executive Summary
Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.
You may also be interested in...
Sweden Urges Pharma To Engage In AMR Initiative
Sweden is testing ‘pull incentives’ in hopes of finding viable reward mechanisms that would ensure adequate access to important antibiotics to meet the Scandinavian country’s domestic internal needs.
AMR Crisis Experts See Hopeful Signs For 2020
2020 could be a watershed year in tackling AMR, but success needs market reforms that ensure new antibiotics get to market and prevent innovators going bust, experts tell Scrip.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.